Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN

Day One Biopharmaceuticals Stock Analysis & Ratings

DAWN Stock Chart & Stats

Day’s Range$6.83 - $7.3
52-Week Range$6.53 - $28.70
Previous Close$6.88
Volume155.91K
Average Volume (3M)230.98K
Market Cap$445.77M
P/E Ratio-2.6
Beta1.00
Next EarningsAug 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart Score7
EPS (TTM)-2.76


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

DAWN FAQ

What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $6.53 and its highest was $28.70 in the past 12 months.
    What is Day One Biopharmaceuticals’s market cap?
    Day One Biopharmaceuticals’s market cap is $445.77M.
      What is Day One Biopharmaceuticals’s price target?
      Currently, no data Available
      What do analysts say about Day One Biopharmaceuticals?
      Day One Biopharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
        When is Day One Biopharmaceuticals’s upcoming earnings report date?
        Day One Biopharmaceuticals’s upcoming earnings report date is Aug 09, 2022 which is in 78 days.
          How were Day One Biopharmaceuticals’s earnings last quarter?
          Day One Biopharmaceuticals released its earnings results on May 12, 2022. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.385 by -$0.095.
            Is Day One Biopharmaceuticals overvalued?
            According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Overvalued.
              Does Day One Biopharmaceuticals pay dividends?
              Day One Biopharmaceuticals does not currently pay dividends.
              What is Day One Biopharmaceuticals’s EPS estimate?
              Day One Biopharmaceuticals’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Day One Biopharmaceuticals have?
              Day One Biopharmaceuticals has 61,910,000 shares outstanding.
                What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
                Day One Biopharmaceuticals reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.385. Following the earnings report the stock price went up 10.072%.
                  Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
                  Among the largest hedge funds holding Day One Biopharmaceuticals’s share is RA Capital Management. It holds Day One Biopharmaceuticals’s shares valued at 60M.

                    ---

                    Day One Biopharmaceuticals Stock Analysis

                    Smart Score
                    7
                    Neutral
                    1
                    2
                    3
                    4
                    5
                    6
                    7
                    8
                    9
                    10
                    Price Target
                    No data currently available
                    The Day One Biopharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Day One Biopharmaceuticals

                    Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

                    ---
                    Popular Stocks

                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis